Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NewAmsterdam Pharma (NAMS) Change in Accured Expenses (2023 - 2025)

NewAmsterdam Pharma's Change in Accured Expenses history spans 3 years, with the latest figure at $5.3 million for Q4 2025.

  • For Q4 2025, Change in Accured Expenses rose 122.39% year-over-year to $5.3 million; the TTM value through Dec 2025 reached $2.4 million, up 45.2%, while the annual FY2025 figure was $2.4 million, 45.2% up from the prior year.
  • Change in Accured Expenses for Q4 2025 was $5.3 million at NewAmsterdam Pharma, up from $638000.0 in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $9.3 million in Q3 2023 and bottomed at -$5.8 million in Q4 2023.
  • The 3-year median for Change in Accured Expenses is $520000.0 (2024), against an average of $800333.3.
  • The largest YoY upside for Change in Accured Expenses was 431.0% in 2025 against a maximum downside of 258.65% in 2025.
  • A 3-year view of Change in Accured Expenses shows it stood at -$5.8 million in 2023, then soared by 141.3% to $2.4 million in 2024, then soared by 122.39% to $5.3 million in 2025.
  • Per Business Quant, the three most recent readings for NAMS's Change in Accured Expenses are $5.3 million (Q4 2025), $638000.0 (Q3 2025), and $1.4 million (Q2 2025).